Aims. In the field of anaesthesia and intensive care, the controlled release systems capable of delivering constantly local anaesthetics are of interest because of the advantages brought to pain management. In this paper we presented the release profiles by usage of siloxane matrices of two common local anaesthetics, lidocaine and bupivacaine, analysed in vitro.
Introduction
Studies on controlled release systems of biologically active compounds have escalated in recent years due to the benefits they bring in the current medical practice [1] [2] [3] . Controlled release systems are made from materials able to encapsulate the active compound in a polymer network and to deliver it in a biological system consistently for a long period of time. The research on the precursors of these systems is further developing, because of the rigorous parameters that must be fulfilled such as bioavailability, biodegradability, full preservation of the active entrapped compound structure and low cost of the manufacturing process [4, 5] . Silica gels are inorganic polymers obtained through the solgel technique [6] . Currently, these materials are studied as potential systems for the controlled release of biologically active compounds, because of their basic characteristics, among which we mention the porosity of the matrix, bioavailability and biodegradability. They are synthetized under normal temperature and pressure conditions and silica gels are approved by the Food and Drug Administration (FDA) [7, 8] , being equally DOI: http://dx.doi.org/10.21454/rjaic.7518/232.vit tolerated by the human organism in oral, interstitial or topical administration. Porous silica gels are obtained by condensation and polycondensation of hydroxylated units obtained through the hydrolysis of some precursors [9, 10] . Based on the precursor selection, various inorganic or hybrid matrices can be obtained, with different properties such as biofunctionality, controllable porosity, high mechanical and thermal stability and different surface tensions. Immobilization of the active agent is made in the "sol" stage, followed by condensation and maturation when it becomes a solid product [11] .
Local anaesthetics are among the most used compounds in pain control [12, 13] . However, there are a number of limitations to the use of these compounds such as the short duration of action and the increased risk of systemic toxicity. Currently, in order to maintain a prolonged analgesia, catheters are used, and through these catheters, doses of local anaesthetics are delivered repeatedly or continuously [14, 15] . This technique is often associated with infections caused by the catheter, increased toxicity, overdose, increased patient discomfort, as well as a high morbidity rate [16] [17] [18] . Bupivacaine and lidocaine are mentioned among the most commonly used local anaesthetics in acute and chronic pain management [19, 20] . No studies with regard to the controlled release of local anaesthetics from siloxane matrices have been found in the literature.
In this paper, the primary goal was to investigate the kinetic profiles of controlled release of bupivacaine and lidocaine, in vitro, from siloxane matrices obtained from two different precursors. The secondary goal was to analyse variations in the controlled release kinetics induced by the modification of parameters such as pH or temperature.
Materials and methods

Materials
Tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), ethanol (EtOH) 99.8% solution, 1N HCl solution, sodium fluoride, disodium phosphate and monosodium phosphate were purchased from SigmaAldrich (St. Louis, MO, USA). Bupivacaine hydrochloride and lidocaine hydrochloride were obtained from Sigma-Aldrich (St. Louis, MO, USA).
All the reagents used in the experimental study are of analytical purity and were used without any prior purification. Spectrophotometric analyses were performed using a UV-VIS Metertech SP 8001 spectrophotometer (Metertech, Taipan, Taiwan). For the controlled release experiments a Heidolph Inkubator 1000 / Heidolph Unimax 1010 system (Heidolph Instruments GmbH & Co., Schwabach, Germany) has been used.
Encapsulation stage
The silica gels were obtained using a two-stage method in accordance with the methods described in the literature [6, 21, 22] . In the first step the sol was obtained by typical methods of synthesis using two different precursors, tetraethoxysilane and tetramethoxysilane. The two different sols were obtained by magnetic stirring (500 rpm) of 5 mL precursor with 5 mL ethanol 99.8%, 4 mL double distilled water and 0.1 mL of HCl 1N for one hour. The sols thus prepared were matured at a constant temperature of 3°C in airtight bottles for 48 hours. In the second stage, the sol was mixed with EtOH, 2 mL lidocaine 10 mg/mL or 4 mL bupivacaine 5 mg/mL and 0.1 mL of NaF 1 M. Magnetic stirring continued until complete gelation of the system. The gel was kept for 48 hours at a constant temperature of 3°C in airtight bottles. In the next step the gel was washed with 10 ml of n-hexane under magnetic stirring (200 rpm) for 10 minutes, then filtered and dried at 25°C for 48 hours. After drying, the gels were milled, weighed and stored in a dry, airtight container at 3°C. The filtrates were also analyzed spectrophotometrically, in order to identify the amount of local anaesthetic lost in the washing process.
Release stage
The controlled release was performed in aqueous systems at different temperatures and pH. The temperatures at which the controlled systems were analysed were 30°C, 36.5°C and 40°C. The temperature of the medium was optimized using the incubator, and the pH of the controlled release systems was optimized by using buffers to provide a pH of 6, 7 and 8. The buffer systems were prepared mixing: for pH 6: 12 mL of Na 2 HPO 4 1M and 88 mL NaH 2 PO 4 1M, for pH 7: 57.7 mL Na 2 HPO 4 1M and 42.3 mL NaH 2 PO 4 1M, and for pH 8: 93.2 mL Na 2 HPO 4 1M and 6.8 mL NaH 2 PO 4 1M. The pH value of the released solution was verified using two different samples with the help of a pH measuring instrument: pH Testo 206-pH3 (Testo, Lenzkirch, Germany).
In the artificial systems 25 mL of buffer solution and 150 mg of gel were introduced. The controlled release of local anaesthetics was studied under continuous magnetic stirring (100 rpm) for 72 hours. At the appointed time, from the system equal samples of 2 mL were taken, then filtered and analysed spectrophotometrically. After each sampling, 2 mL of buffer solution was introduced in the system, to keep unchanged the initial volume. A calibration curve was used to calculate the concentration of local anaesthetic released from the silica gel. For the two local anaesthetics, the standard solution was diluted to 0.5 mg/ mL, 0.625 mg/mL and 0.75 mg/mL in double distilled water. The solutions thus obtained were scanned on a LD, lidocaine; BP, bupivacaine; C, control; LA, local anaesthetic; TEOS, tetraethoxysilane; TMOS, tetra methoxysilane
Results
In Table 1 , the characteristics of the obtained silica gels are summarized.
The gelling time varied between 9 and 15 minutes depending on the type of the precursor used. Thus, for gels obtained from TEOS the gelling time varied between 13 and 15 min, median value 14 and from TMOS was between 9 and 11 min, median value 10. The maximum absorption was at 263 nm in the case of lidocaine and at 262 nm for bupivacaine (Figure 1) . For calculating the concentration of the local anaesthetics released, a calibration curve was used for both types of anaesthetics. The regression coefficient was 0.9972 for lidocaine and 0.9994 for bupivacaine both indicating a strong value significance.
To determine after encapsulation the local anaesthetics released from silica matrix the filtrates obtained from washing the gels were analysed. The spectrophotometric analyses have not detected any concentration of local anaesthetic in the filtrate.
The release profiles of lidocaine had a number of characteristics due to the type of release system and to the type of precursor used in the gel synthesis. Figure 2 presented the release profiles of lidocaine from the two types of gels, according to the parameters set for each type of artificial controlled release system. There was no significant difference noted in the released concentrations of lidocaine, from the statistical point of view related to its kinetics, in systems having different pH and type of matrix (p > 0.05). Figure 3 shows the release kinetics of bupivacaine from the artificial systems. Bupivacaine presented a similar release profile with no significant modifications with regard to the final concentration of the released anaesthetic in systems with different pH and matrix type (p > 0.05).
The prolonged release duration of the local anaesthetic is an important advantage of the matrix. How UV spectrophotometer in the range 200-400 nm. For all the samples, the absorbance of the solutions was determined by a spectrophotometer.
The local anaesthetic concentration was calculated based on the calibration curve. The lidocaine samples were read at 262 nm and the bupivacaine ones at 263 nm. For both anaesthetics a calibration curve was obtained in a concentration range of 0.125 mg/mL -1.25 mg/mL. All experiments were performed in duplicate. Six silica gels were obtained by the sol-gel technique in two steps. In two samples the active substance was not entrapped and these were used as control samples in the statistical calculations.
The kinetics of in vitro release was studied in aqueous systems. Two parameters were varied: temperature (30°C, 36.5°C, 40°C) and pH (6, 7, 8) . Thus, nine systems of artificially controlled release were obtained in which the variables, temperature and pH, were combined. In each system the release profile of each type of gel was investigated. The release kinetics was studied for 72 hours in each case.
Statistical analysis
The statistical analysis was performed using specialized software for Mac OS X 6 Prism v. Table 2 . We observed a progressively increase in the concentration of the released local anaesthetics with increasing the temperature. Unlike pH, which did not influence the kinetics of the release, the temperature was found to influence the kinetics, but in a different way. Conforming to the data presented in Table 2 , the release of both local anaesthetics from the matrix increased in parallel with the rise in temperature.
Data are presented in Table 3 . Regarding lidocaine release from TEOS, significant differences were noted between 30°C vs. 36.5°C and 30°C vs. 40°C. There were no significant differences between 36.5°C vs. 40°C. A similar increase was noted in the case of the release of lidocaine from TMOS, between 30°C vs. 36.5°C and 30°C vs. 40°C and not significant increase in case of 36.5°C vs. 40°C (p = 0.1694) temperature variation. Regarding bupivacaine release from the siloxane matrix, it increased significantly from both TEOS and TMOS up to 36.5°C and no further increase was noted at 40°C. At this temperature the concentration did not change with TMOS (p > 0.05) or even decreased with TEOS (p = 0.0144).
Discussion
In our study no statistically significant differences were found regarding the effect of pH on the yield of the active compound release. Rao et al. have studied the influence of changes in the pH on the release kinetics of active substances. Following their study, they identified significant differences regarding the yield of the active compound release with a pH of 6.8, in comparison to those with a pH of 1 [21] .
Another parameter that varied in our study was the temperature of artificial controlled release systems. The selected temperature range was made in accordance with the physiological temperature of the human body. From the kinetic analyses performed and from the statistical interpretation of the results, a higher concentration of local anaesthetic was registered in the systems operated at a higher temperature. In case of lidocaine, the release from the both matrices increased with raising the temperature up to 40°C. The release kinetics of bupivacaine showed a limited increase, up to 36.5°C. Surprisingly, the amount of bupivacaine released at 40°C significantly decreased in the case of TEOS (p = 0.0144) ( Table 3 ). The decrease of the amount of the released bupivacaine in spite of increasing the temperature to 40°C is difficult to explain. These characteristics are most probably influenced by the hydrolysis of the silaxanic bondings, as well as of the breaking bonds between the siloxanic matrix and the anaesthetic. Under the increased temperature conditions new hydrogen bounds could appear between the bupivacaine molecule and the siloxane matrix, and the interconnections between the matrix molecules could also be modified. Siloxane matrix structure is highly influenced by the type of precursor used in the manufacture of the gel. Moreover, the matrix structure directly influences the release profile of the active compound. However, the modified kinetics at 40°C was registered with both matrixes, and seemed rather to depend on the local anaesthetic's structure.
We found a prolonged release of the local anaesthetic up to 72 hours, longer than the data from the literature. In a similar study Zhang et al. [22] entrapped bupivacaine in poly-(DL-lactic-co-glycolic) acid microspheres, highlighting 24 hour long concentration maintenance. With regard to the histocompatibility of these systems, Teoli et al. [23] studied these aspects in a study regarding the release of proteins from siloxane systems. Following their study they could not identify significant changes regarding the inflammatory reactions generated by the siloxane matrices. The same biological tolerance and also the capacity of an extended release of local anaesthetics (lidocaine and bupivacaine) were found by Peng et al. in the silicone hydrogel contact lenses loaded with vitamin E [24] .
The limitations of this study are mainly represented by the lack of analysis for release profiles for local anaesthetics in the case of in vivo systems, but at this stage it did not represent the aim of our research. Moreover, we consider that another limitation of this paper is given by the lack of homogeneity for pressure and atmospheric humidity levels in the laboratory where the study has been carried out and probably the lack of use of High Performance Lipid Chromatography (HPLC).
In conclusion, the use of controlled release systems of local anaesthetics based on siloxane matrices might be useful in the clinical practice, considering the importance of maintaining a constant concentration of anaesthetics for a longer period of time. However, further studies are required regarding the histo- Metode. Matricele siloxanice au fost obţinute în concordanţă cu metodele descrise în literatura de specialitate. Pentru sinteza acestora s-au utilizat tetraetoxisilan (TEOS) şi tetrametoxisilan (TMOS) ca precursori. În gelurile astfel sintetizate, s-au înglobat lidocaină şi bupivacaină. Pentru analiza eliberării de anestezice sau realizat sisteme artificiale in vitro, la care s-a variat temperatura (30°C, 36.5°C, 40°C) şi pH-ul (6, 7, 8) .
Rezultate. În urma analizelor sistemelor artificiale obţinute, au fost evidenţiate profiluri de eliberare asemănătoare pentru ambele anestezice. Au fost identificate diferenţe semnificative statistic pentru sistemele la care eliberarea s-a realizat la temperaturi mai mari de 36.5°C (p < 0,05). Nu au fost evidenţiate diferenţe semnificative statistic în ceea ce priveşte influenţa pH-ului, tipul de anestezic care a fost imobilizat, respectiv tipul de precursor care a fost utilizat la sinteza matricelor siloxanice.
Concluzii. În urma acestui studiu experimental s-a evidenţiat că pH-ul, tipul de precursor sau tipul de anestezic local imobilizat nu influenţează semnificativ statistic capacitatea de eliberare. În concluzie, putem afirma că aceste sisteme sunt promiţătoare pentru obţi-nerea de preparate farmaceutice care pot fi utilizate cu succes în practica clinică curentă. Totuşi, trebuie efectuate o serie de studii cu privire la eliberarea controlată de compuşi biologic activi din matricele siloxanice atât pentru sisteme in vitro, cât şi pentru sisteme in vivo. Mai mult decât atât, trebuie verificate cu stricteţe implicaţiile histopatologice şi posibilele reacţii toxice pe care sistemele siloxanice pot să le aducă.
Cuvinte cheie: anestezice locale; controlul durerii; matrice siloxanice; eliberare controlată de medicamente
